16 News from the research and development department by Pharmexa for the biotechnology industry

Tip: You can further refine your news selection by topics.

16 News from the research and development department by Pharmexa for the biotechnology industry

Tip: You can further refine your news selection by topics.

Pharmexa presents data from influenza program

25-Jun-2007 - Pharmexa-Epimmune, the U.S.-based subsidiary of Pharmexa A/S, presented selected data from its influenza vaccine program at the Influenza Conference entitled, "Options for the Control of Influenza VI," held in Toronto, Ontario, Canada. The company's "universal" vaccine strategy combines the use ...

laboratories T cells vaccines

Pharmexa starts pivotal phase III trial in the United States

07-May-2007 - The FDA has approved Pharmexas IND to start the PrimoVax trial in the United States. PrimoVax is a pivotal phase III trial testing the peptide vaccine GV1001 in patients with non-resectable pancreatic cancer. According to the plan the trial will enrol a total of 520 patients with pancreatic ...

Denmark orphan drugs pancreatic cancer

British doctors to start new phase III trial with Pharmexa's GV1001

19-Mar-2007 - A Phase III trial testing a new treatment for pancreatic cancer has now been initiated. Pharmexa has developed the drug and is co-financing the trial together with pharmaceuticals company Roche and Cancer Research UK. Referred to as the TeloVac trial, the recently initiated Phase III trial is a ...

chemotherapy education immune cells

Pharmexa has started phase II trial in liver cancer with GV1001

29-Nov-2006 - The first patient has been treated in the HeptoVax phase II trial of GV1001 in liver cancer, following receipt of the required approvals in France, Spain and Germany. The HeptoVax trial is a phase II trial evaluating the safety and efficacy of GV1001 in advanced hepatocellular carcinoma ("HCC" or ...

cyclophosphamide Germany hepatocellular carcinoma

Pharmexa receives patent in the United States and Europe on new vaccine candidate

12-Sep-2006 - Pharmexa has been granted a patent in the United States and has received communication of intent to grant from the European patent authorities on GV1003, a new peptide vaccine candidate aimed at the telomerase enzyme which is crucial to cancer cells' ability to divide. The telomerase enzyme, ...

amino acids mutations patents

Pharmexa receives approval of Phase II application with GV1001 in liver cancer

01-Sep-2006 - Pharmexa has received the necessary approvals in France regarding the Heptovax Phase II trial with GV1001 in liver cancer and will now initiate recruitment of patients. Approvals in Spain and Germany are expected within the next few weeks. The Heptovax trial is a Pase II trial evaluating the ...

cyclophosphamide Germany hepatocellular carcinoma

New results published on Pharmexa's PADRE® epitope in Alzheimer's vaccine

29-Aug-2006 - A group of scientists from the Institute of Molecular Medicine at Huntington Beach (California) and the Institute of Brain Aging and Dementia at the University of California has published new pre-clinical data on an experimental Alzheimer's vaccine incorporating Pharmexa's proprietary PADRE® ...

Alzheimer's disease dementia medicine

Pharmexa receives orphan drug status for GV1001 for pancreatic cancer in the US

28-Jul-2006 - FDA has granted orphan drug status to Pharmexa for the peptide vaccine GV1001 for the treatment of pancreatic cancer. Orphan drug status is granted in the United States to drugs aimed at diseases affecting less than 200,000 people in the United States. Orphan drug status in the United States ...

diseases orphan drugs pancreatic cancer

Pharmexa will start phase II trial in liver cancer with GV1001

02-Jun-2006 - Pharmexa has submitted the application to initiate the Heptovax phase II trial. The trial is planned to start in the third quarter of 2006 and will include up to 41 liver cancer patients. The Heptovax trial is a phase II, open-label trial evaluating the safety and efficacy of GV1001 in advanced ...

Germany hepatocellular carcinoma liver cancer

Pharmexa receives US patent on the GV1001 vaccine for chemotherapy

26-Apr-2006 - The US patent authorities have issued a patent to Pharmexa on the GV1001 vaccine. GV1001 is Pharmexa's peptide vaccine targeting telomerase, which is currently under preparation for Phase III trials in pancreatic cancer. Pharmexa already has issued and validated patents for the GV1001 vaccine in ...

pancreatic cancer patents peptides
Search all
Haven't found the right news yet?

The bionity.com news search

Start your targeted search now with a wide range of filter options. Our database includes an archive of 27,244 life science news from business and science, which you can search by topic and organization, filtered by time and geography.

Start news search now